Special Event: Invitation-only breakfast roundtable featuring information and insight on business and partnership opportunities in Denmark.
For information on receiving an invitation to this exclusive event, contact Nathan Tinker, email@example.com.
- 2:00 PM
Registration Desk Open
- 3:00 PM
Exhibition Hall Open
- 9:15 AM
Governor Howard Dean - former DNC Chairman, presidential candidate
and six-term Governor
Howard Dean is a Senior Strategic Advisor and Independent Consultant for the Government Affairs practice at McKenna Long & Aldridge LLP. He focuses on health care and energy issues, as well as providing expertise derived from his extensive experience in public office.
A recognized thought-leader in health care reform, Governor Dean works with clients to navigate complicated regulations and political challenges in both the private and public sectors. Through partnering industry with business and community interests he is at the forefront of promoting high quality and affordable health care while supporting innovation.
- 9:45 AM
D&O Issues Affecting Private and Public Life Science Companies Directors and Officers Insurance issues are increasingly important to both private and public Life Science companies. Directors have always been bound by many duties arising under jurisdictional laws. The difference in today‚Äôs world is that stakeholders have far greater forms of remedy against directors and there is an increased willingness to pursue claims against them. Whether or not the director is ultimately held liable for such claims, the defense costs associated can be extremely expensive, and the process can take up months or even years of a director's valuable time. In practice, once a claim is alleged against a director for any wrong doing they have two sources of protection-they can either turn to the company to seek indemnification or they can seek assistance from a D&O policy.
- 11:30 AM
Bioscience Industry Showcase 3
- 12:00 PM
Innovation Alley Poster Session 3
- 10:30 AM
Alzheimer's Drug Discovery in New York City This panel session will include a range of speakers from Academia and Biotech in New York City who will discuss innovative approaches to drug discovery for Alzheimer’s disease. Programs on cognitive enhancers, tau immunotherapy, neuroimaging technology, and small molecule modulation of protein folding will all be presented. ADDF’s Howard Fillit will discuss the role of venture philanthropy in bridging academia and biotech to accelerate innovation and to build a critical mass of NYC effort for this devastating and critically important fatal disease.
- 10:30 AM
In re Bilski, Prometheus v Mayo, and ACLU v Myriad: How Current Cases Impact Patent Eligibility The bounds of patent-eligibility under 35 U.S.C. 101 are being tested in a number of pending cases. This renewed interest in Section 101 could lead to dramatic changes in the types of inventions can and cannot be patented, such as diagnostic methods important to the development of personalized medicine as well as isolated and purified natural substances. This session will discuss the pending cases with special emphasis on the directions the courts are taking with regard to biotech inventions. The session will also offer strategies and best practices for prosecuting patents in the face of these potential shifts in eligibility standards.
- 10:30 AM
Surviving the Cash Crunch Current economic realities are changing traditional models for biotechnology funding. With venture capital and private equity funding limited, and being invested with greater scrutiny of potential return, companies are asking where else to look for cash. This panel is for those seeking the "gooses laying golden eggs" before their goose is cooked. The panel will point to new and little understood funding sources such as: economic stimulus opportunities, tax credits, government grants, strategic partnerships and more.
- 10:00 AM
Coffee Break (in Exhibition Hall)
- 11:15 AM
Addressing ADR In Life Sciences Enterprises This panel will include lawyers and business executives, for an examination of alternative dispute resolution in life sciences enterprises. With the rising costs and burdens of civil litigation, arbitration and mediation can be important, cost-effective alternatives for companies large and small. A wide variety of disputes lend themselves to ADR, including intellectual property disputes such as patents, trademarks and licensing. ADR is well-suited to today's global economy, where disputes of international scope are on the rise. An overview of ADR for life sciences companies will be provided, and panelists will share their unique views and experiences.
- 11:15 AM
Are New York And It's Universities Doing Enough To Commercialize Academic Technologies New York State has world renowned universities with new and developing technologies and engaged economic development agences. Although both groups see the opportunity and associated economic development, are they working together on commercialization, like other states, to take advantage of the future possibilities? Are they working with the financial capital of the world to help? What are the missing pieces?
- 2:30 PM
Luncheon and Keynote Address
Super Bowl champion Jerome "The Bus" Bettis
Sponsored by: PhRMA
Abram Bettis, nicknamed "The Bus" (born February 16, 1972 in Detroit, Michigan), is a former National Football League running back for the Pittsburgh Steelers. Bettis is considered one of the best big backs of his era, and is fifth on the league’s all-time rushing list. He retired in 2006 after a Super Bowl victory in which he ran for 43 yards on 14 attempts.
- 3:00 PM
Michael Holman, Research Director, Lux Research
Holman is a Research Director at Lux Research. He leads a team of Analysts and Senior Analysts responsible for providing ongoing intelligence and strategic advice to clients in a variety of emerging technology areas, including nanomaterials, solar energy, alternative power and energy storage, water technologies, and biosciences. He and his research team provide the information and insight to help clients -- ranging from Global 500 corporations to leading institutional investors -- make better decisions about emerging technologies. Michael is also deeply involved in technology public policy issues. He is a member of the President's Council of Advisors on Science and Technology (PCAST) Nanotechnology Technical Advisory Group, and was invited to address policymakers from the U.S. and EU at the Perspectives on the Future of Science and Technology program. He has helped the U.S. Department of Energy (DOE) organize its Nanomanufacturing for Energy Efficiency Workshop, and helped draft a roadmap document for the DOE, guiding hundreds of millions of dollars in spending.
Michael holds a Ph.D. in Chemistry from Columbia University, where he performed cutting-edge research as a part of Columbia’s Nanoscale Science and Engineering Center and authored numerous scientific articles and reviews. He also holds a B.A. in Chemistry and Philosophy from Rice University.
- 3:45 PM
Scott Rickert, Ph.D., President, Co-Founder and CEO, Nanofilm
E. Rickert is President, Co-Founder and Chief Executive Officer
Dr. Rickert is one of Nanofilm's original founders. He was responsible for the original concepts that launched Nanofilm into the nanotechnology arena. Dr. Rickert was instrumental in the development of the company's first coating called "Clarity" and continues to set the vision for the company's R&D team. Dr. Rickert brings a depth of research expertise to the company from his strong academic background; he was a Professor at Case Western Reserve University from 1980 to 1987. He holds a B.S. from Cornell University and a Ph.D. from Case Western Reserve University. He currently holds positions on a number of key industry groups, including the Global Advisory Board of the NanoBusiness Alliance. Dr. Rickert frequently lectures and writes on topics in the field.
3:45 PM - 4:15 PM
Keynote Speaker: Scott Livingston
Scott Livingston is Chairman and Chief Executive Officer of Livingston
Securities LLC. Mr. Livingston has been working on emerging technologies
at Wall Street firms for over 18 years and has specialized in nanotechnologies
since 2002. Mr. Livingston has been called "sharp and highly
connected" by the Forbes Wolfe Nanotechnology Report (July
1, 2005) and has been a keynote speaker on advanced technology
investment trends at MIT, the National Renewable Energy Lab (NREL),
the Nanobusiness Alliance, Brookhaven National Labs, Rice University
Center for Nanotechnology, the Lawrence Berkeley Labs, Albany
Nanotech, Hillary Clinton's Jobs for New York, the US Congress
Nanotechnology Caucus and the US Congress High Tech Caucus, and
at conferences on economic development and job creation through
investment in advanced technologies in over a dozen states across
America. In addition, Mr. Livingston is also the creator of the
annual "Livingston Nanotechnology Conference," Wall
Street's largest annual nanotechnology investor conference since
Durando is a long time, successful entrepreneur. He has a background in both
engineering and corporate finance. Ron has been Chief Operating Officer of
Microphase since 1994. When he joined Microphase, he worked with founder Ned
Ergul to revive the corporation and adjust both its mission and operating style
to accommodate changes in the market. He was instrumental in turning around
the company and has doubled its revenues during his tour as Chief Operating
Officer. Ron started and successfully ran an RF Contract Manufacturing based
in China in from August 1996 until December 2008. The company grew from 6 employees
operating in 6500 sq feet to over 1000 employees at it’s peek in a 150,000 square foot facility.
In October 1996 he founded mPhase Technologies, Inc. He has been its President and Chief Executive Officer since the company’s inception. Under Ron’s leadership mPhase produced and sold a very successful line of DSL components and he has now completed the transition of mPhase into a battery technology company that is now developing an innovative battery technology based upon breakthroughs in Microfludics and Nanotechnology.
4:45 PM - 5:30 PM
Keynote Speaker: Douglas Jamison,
Chairman, CEO and Managing Director, Harris & Harris Group
Jamison is Chairman and Chief Executive Officer and a Managing
Director of Harris & Harris Group, Inc., a publicly
traded venture capital company listed on the Nasdaq Global Market
(NASDAQ: TINY). Harris & Harris Group focuses solely
in making initial investments in “tiny” technologies,
which it defines as nanotechnology and microsystems.
He has previously held the positions of President, Chief Operating
Officer and Chief Financial Officer of Harris & Harris Group,
Inc. He is also currently Chairman and Chief Executive
Officer of Harris & Harris Enterprises, Inc., a wholly owned
subsidiary of Harris & Harris Group. He is a member
of the Board of Directors of Ancora Pharmaceuticals, Inc., and
a Board observer in Mersana Therapeutics, Inc., Solazyme, Inc.,
Nextreme Thermal Solutions, Inc., and Metabolon, Inc., privately
held nanotechnology-enabled portfolio companies of Harris & Harris
Group. He is Co-Editor-in-Chief of “Nanotechnology
Law & Business.” He is Co-Chair of the Advisory
Board, Converging Technology Bar Association, a member of the
University of Pennsylvania Nano-Bio Interface Ethics Advisory
Board, and a member of the Advisory Board, Massachusetts Technology
Collaborative Nanotechnology Venture Forum. Prior to joining
Harris & Harris Group, he was a Senior Technology Manager
at the University of Utah Technology Transfer Office, where he
managed intellectual property in physics, chemistry and the engineering
sciences. He is a graduate of Dartmouth College (B.A.,
1992) and the University of Utah (M.S., 1999).